All In Biotech

Free tool

FAERS Monitor: Coly-Mycin S

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050356 or its brand name (Coly-Mycin S, Colistin Sulfate, Hydrocortisone Acetate, Neomycin Sulfate, Thonzonium Bromide). Reports on generic versions are filed under their own applications.

Reports

2

Serious

2

100% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthenia1
  • central nervous system lymphoma1
  • colitis1
  • dehydration1
  • diarrhoea1
  • dizziness postural1
  • dysstasia1
  • endophthalmitis1
  • fatigue1
  • general physical health deterioration1
  • malignant neoplasm progression1
  • nausea1
  • ocular discomfort1
  • oedema peripheral1
  • pollakiuria1

Reports by year received

View as table
YearReports
20221
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
central nervous system lymphoma17639.41908.61,908
endophthalmitis11753.3438.4437
dizziness postural11084.7271.2270
ocular discomfort1936.7234.2233
dysstasia1360.290.189
colitis1277.469.468
pollakiuria1252.263.162
malignant neoplasm progression1102.725.725
general physical health deterioration190.922.722
oedema peripheral186.321.621
dehydration178.819.719
asthenia128.07.06
diarrhoea116.34.13
fatigue113.53.43
nausea113.33.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.